Hematuria Treatment Market Research Report -Forecast to 2027

Hematuria Treatment Market Share, Insights And Growth Analysis By Type (Gross, Microscopic And Others), By Causes (Kidney Stones, Prostate Cancer, And Urethritis), By Treatment (Drugs And Therapies), By End-Users (Hospitals, Clinics, And Labs) - Forecast Till 2027

ID: MRFR/MED/1200-HCR | | Region: Global | 85 Pages         

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Hematuria Treatment Market Information, by Type

6.1 Introduction

6.2 Gross or Macroscopic Hematuria

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3 Microscopic hematuria

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4 Idiopathic hematuria

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.5 Jogger’s hematuria

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 7. Global Hematuria Treatment Market Information, by Causes

7.1 Introduction

7.2 Kidney stones

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3 Urinary tract infections (UTI)

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4 Urethritis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5 Blood cancer

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.6 Bladder stones

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.7 Prostate cancer

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.8 Cystitis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.9 Trauma

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.10 Vigorous exercise

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.11 Polycystic kidney disease

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.12 Endometriosis

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.13 Menstruation

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 8. Global Hematuria Treatment Market Information, by Treatment

8.1 Introduction

8.2 Drugs

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3 Therapeutics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 9. Global Hematuria Treatment Market Information, by End-Users

8.1 Introduction

8.2 Hospitals

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3 Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4 Laboratories

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.5 Research centers

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.6 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 10. Global Hematuria Treatment Market Information, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 UK

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia-Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 South Korea

10.4.6 Rest of Asia-Pacific

10.5 Middle East & Africa

10.5.1 Middle East

10.5.2 Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

Chapter 12. Company Profiles

12.1 AstraZeneca Plc.

12.1.1 Company Overview

12.1.2 Type Overview

12.1.3 Financials Overview

12.1.4 Key Developments

12.1.5 SWOT Analysis

12.2 Bristol-Myers Squibb

12.2.1 Company Overview

12.2.2 Type Overview

12.2.3 Financials Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 F. Hoffmann-La Roche Ltd

12.3.1 Company Overview

12.3.2 Type Overview

12.3.3 Financials Overview

12.3.4 Key Developments

12.3.5 SWOT Analysis

12.4 GlaxoSmithKline Inc.

12.4.1 Company Overview

12.4.2 Type Overview

12.4.3 Financials Overview

12.4.4 Key Developments

12.4.5 SWOT Analysis

12.5 Janssen Pharmaceuticals, Inc.

12.5.1 Company Overview

12.5.2 Type Overview

12.5.3 Financials Overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 Merck & Co.

12.6.1 Company Overview

12.6.2 Type Overview

12.6.3 Financials Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Novartis International AG

12.7.1 Company Overview

12.7.2 Type Overview

12.7.3 Financials Overview

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Pfizer, Inc.

12.8.1 Company Overview

12.8.2 Type Overview

12.8.3 Financials Overview

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 Sun Pharmaceutical Industries Limited

12.9.1 Company Overview

12.9.2 Type Overview

12.9.3 Financials Overview

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 The Medicines Company

12.10.1 Company Overview

12.10.2 Type Overview

12.10.3 Financials Overview

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.11 Others


Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s Viewpoint

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Predictions for the Biosurgery Industry

Chapter 14. Appendix

LIST OF TABLES

Table 1 Global Hematuria Treatment Market Information Synopsis, 2020-2027

Table 2 Global Hematuria Treatment Market Information Estimates and Forecast, 2020-2027 (USD Million)

Table 3 Global Hematuria Treatment Market Information, by Region, 2020-2027 (USD Million)

Table 4 Global Hematuria Treatment Market Information, by Type, 2020-2027 (USD Million)

Table 5 Global Hematuria Treatment Market Information, by Causes, 2020-2027 (USD Million)

Table 6 Global Hematuria Treatment Market Information, by Treatment, 2020-2027 (USD Million)

Table 7 North America: Hematuria Treatment Market Information, by Type, 2020-2027 (USD

Million)

Table 8 North America: Hematuria Treatment Market Information, by Causes, 2020-2027 (USD

Million)

Table 9 North America: Hematuria Treatment Market Information, by Treatment, 2020-2027 (USD

Million)

Table 10 US: Hematuria Treatment Market Information, by Type, 2020-2027 (USD Million)

Table 11 US: Hematuria Treatment Market Information, by Causes, 2020-2027 (USD Million)

Table 12 US: Hematuria Treatment Market Information, by Treatment, 2020-2027 (USD Million)

Table 13 Canada: Hematuria Treatment Market Information, by Type, 2020-2027 (USD Million)

Table 14 Canada: Hematuria Treatment Market Information, by Causes, 2020-2027 (USD Million)

Table 15 Canada: Hematuria Treatment Market Information, by Treatment, 2020-2027 (USD

Million)

Table 16 South America: Hematuria Treatment Market Information, by Type, 2020-2027 (USD

Million)

Table 17 South America: Hematuria Treatment Market Information, by Causes, 2020-2027 (USD

Million)

Table 18 South America: Hematuria Treatment Market Information, by Treatment, 2020-2027 (USD

Million)

Table 19 Europe: Hematuria Treatment Market Information, by Type, 2020-2027 (USD Million)

Table 20 Europe: Hematuria Treatment Market Information, by Causes, 2020-2027 (USD Million)

Table 21 Europe: Hematuria Treatment Market Information, by Treatment, 2020-2027 (USD Million)

Table 22 Western Europe: Hematuria Treatment Market Information, by Type, 2020-2027 (USD

Million)

Table 23 Western Europe: Hematuria Treatment Market Information, by Causes, 2020-2027 (USD

Million)

Table 24 Western Europe: Hematuria Treatment Market Information, by Treatment, 2020-2027

(USD Million)

Table 25 Eastern Europe: Hematuria Treatment Market Information, by Type, 2020-2027 (USD

Million)

Table 26 Eastern Europe: Hematuria Treatment Market Information, by Causes, 2020-2027 (USD

Million)

Table 27 Eastern Europe: Hematuria Treatment Market Information, by Treatment, 2020-2027

(USD Million)

Table 28 Asia-Pacific: Hematuria Treatment Market Information, by Type, 2020-2027 (USD

Million)

Table 29 Asia-Pacific: Hematuria Treatment Market Information, by Causes, 2020-2027 (USD

Million)

Table 30 Asia-Pacific: Hematuria Treatment Market Information, by Treatment, 2020-2027 (USD

Million)

Table 31 Middle East & Africa: Hematuria Treatment Market Information, by Type, 2020-2027

(USD Million)

Table 32 Middle East & Africa: Hematuria Treatment Market Information, by Causes, 2020-2027

(USD Million)

Table 33 Middle East & Africa: Hematuria Treatment Market Information, by Treatment, 2020-2027

(USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Hematuria Treatment Market Information

Figure 3 Segmentation Market Dynamics for Global Hematuria Treatment Market Information

Figure 4 Global Hematuria Treatment Market Information Share, by Type, 2020

Figure 5 Global Hematuria Treatment Market Information Share, by Causes, 2020

Figure 6 Global Hematuria Treatment Market Information Share, by Treatment, 2020

Figure 7 Global Hematuria Treatment Market Information Share, by Region, 2020

Figure 8 North America: Hematuria Treatment Market Information Share, by Country, 2020

Figure 9 Europe: Hematuria Treatment Market Information Share, by Country, 2020

Figure 10 Asia-Pacific: Hematuria Treatment Market Information Share, by Country, 2020

Figure 11 Middle East & Africa: Hematuria Treatment Market Information Share, by Country, 2020

Figure 12 Global Hematuria Treatment Market Information: Company Share Analysis, 2020 (%)

Figure 13 AstraZeneca plc.: Key Financials

Figure 14 AstraZeneca plc.: Segmental Revenue

Figure 15 AstraZeneca plc.: Geographical Revenue

Figure 16 Bristol-Myers Squibb: Key Financials

Figure 17 Bristol-Myers Squibb: Segmental Revenue

Figure 18 Bristol-Myers Squibb: Geographical Revenue

Figure 19 F. Hoffmann-La Roche Ltd: Key Financials

Figure 20 F. Hoffmann-La Roche Ltd: Segmental Revenue

Figure 21 F. Hoffmann-La Roche Ltd: Geographical Revenue

Figure 22 GlaxoSmithKline Inc.: Key Financials

Figure 23 GlaxoSmithKline Inc.: Segmental Revenue

Figure 24 GlaxoSmithKline Inc.: Geographical Revenue

Figure 25 Janssen Pharmaceuticals, Inc.: Key Financials

Figure 26 Janssen Pharmaceuticals, Inc.: Segmental Revenue

Figure 27 Janssen Pharmaceuticals, Inc.: Geographical Revenue

Figure 28 Merck & Co.: Key Financials

Figure 29 Merck & Co.: Segmental Revenue

Figure 30 Merck & Co.: Geographical Revenue

Figure 31 Novartis International AG: Key Financials

Figure 32 Novartis International AG: Segmental Revenue

Figure 33 Novartis International AG: Geographical Revenue

Figure 34 Pfizer, Inc.: Key Financials

Figure 35 Pfizer, Inc.: Segmental Revenue

Figure 36 Pfizer, Inc.: Geographical Revenue

Figure 37 Sun Pharmaceutical Industries Limited: Key Financials

Figure 38 Sun Pharmaceutical Industries Limited: Segmental Revenue

Figure 39 Sun Pharmaceutical Industries Limited: Geographical Revenue

Figure 40 The Medicines Company: Key Financials

Figure 41 The Medicines Company: Segmental Revenue

Figure 42 The Medicines Company: Geographical Revenue

Figure 43 Others: Key Financials

Figure 44 Others: Segmental Revenue

Figure 45 Others: Geographical Revenue


Hematuria Treatment Market

Hematuria treatment market is projected to reach USD 1,103.80 million and expected to grow at a CAGR of 2.7% during the forecast period

Segmentation

By Type Gross Microscopic Others
By Causes Kidney Stones Prostate Cancer Urethritis
By Treatment Drugs Therapies
By End-Users Hospitals Clinics Labs

Key Players

  • Pfizer Inc.
  • GlaxoSmithKline Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Johnson & Johnson
  • Cipla Ltd.
  • Hoffmann La Roche Ltd.
  • Bristol Myers Squibb
  • Novartis International AG.
  • Teva Pharmaceutical Industries Ltd.

Drivers

  • Rising incidence of hematuria increases with people that belong to the age group of above 35 years
  • Rising frequency rate in numerous types of hematuria Increasing awareness
Speak to Analyst Request a Free Sample

Hematuria Treatment Market Outlook


The hematuria treatment market is exposed to great opportunities and market developments that will help in the development of the global market. The global market is further estimated to grow at a exponential CAGR during the forecast period. Hematuria, as a part of the global market, is the presence of blood in a person’s urine. Several causes lead to the presence of blood in the urine of an individual such as urinary tract infections, bladder or kidney stones, and others like kidney infections (pyelonephritis), cancer, enlarged prostate, kidney injury, and the development of kidney disease, as well. Further, there have been various improvements in understanding of the physiological mechanism that can be held responsible for hematuria that has led to developments in the treatment of the medical condition.


The use of antibiotics prescribed for the treatment by doctors is dependent on what part of the track is to be treated or the part where the problem persists. However, the regular developments that occur in route of administration and different concentrations of drugs enable the prevention of the occurrence of the disease or infection to spread to cellular and molecular levels within the body.


COVID 19 Analysis


The sudden outbreak of the fatal coronavirus pandemic has been a major cause of concern for the functionings and treatment extended by the hematuria treatment market in the global scenario for the ongoing forecast period. The arrival of the pandemic has a major disruption in the demand and supply chain mechanism of the global market and the medical professionals are purely dedicated to the treatment of patients that have fallen to the fatalities of the pandemic followed by the rising cases and the non-stop waves of the pandemic of the different infection variants. The operation theaters and other medical rooms are focusing on treating the covid positive patients on priority and the team of doctors and other medical staff is dedicating their services to treat them.


The lockdown that has been imposed followed by the restrictions and social norms that are further creating issues for the expansion of the hematuria treatment market especially during the ongoing forecast period. However, as the number of positive cases is reducing, medical professionals and doctors can physically treat the people who are witnessing other issues. Further, there has been a rise in the research and developments in the medical field that is likely to add to the needful requirements of the market at this hour and hence, play an important role in its expansion in the global hematuria treatment market scenario especially during the ongoing forecast period.


Hematuria Treatment Market Dynamics


Drivers


There has been a rising incidence of hematuria increases with people that belong to the age group of above 35 years of age are more likely to develop the symptoms of hematuria. According to the information that has been circulated by the International Incontinence Society, 70% to 80% of people aged 80 years experiences symptoms of an overactive functioning of the bladder. The substantial rise in the geriatric population is expected to increase the patient pool globally, which in turn is projected to propel the global growth of the hematuria treatment market during the forecast period. According to the information of the World Health Organization (WHO), the global geriatric population is anticipated to reach around an approximate figure of 2 billion that accounts for 22% of the global population by 2050 as compared to 617 million in the historic period of 2015.


Restraints


However, the arrival of the pandemic followed by the decline in the availability of medical professionals to offer hematuria treatment is likely to hamper the operations and the anticipated market growth that has been set for the forecast period that will be ending in 2027. Also, the lockdown has resulted in the disruption of the management and market functioning followed by the lack of awareness and knowledge about the treatment is likely to pose as major restraints that might hamper the global market growth.


The rising role of technology followed by the high prevalence of diseases such as UTI and kidney stones is likely to help in the positive expansion of the hematuria treatment market during the ongoing forecast period. There has been an increase in the incidence of hematuria among various categories of adults, followed by a surge in awareness, extensive research, expansion, and development activities. The prominent advent of high-throughput screening (HTS) for drug discovery, along with the FDA approvals for drugs are the major factors driving the global size of the hematuria treatment market. Currently, the societal cost of UTI infections that extend to health care costs and time missed from work, is estimated to have reached around US$ 3.5 Bn per year in the U.S. alone.


Hematuria Treatment Market Segment Overview


The hematuria treatment market has been segmented based on the following to meet the varied needs of the global target audience that is spread in a series of locations that are participating in the market functioning.


Based on the Drug Type



  • Quinolones

  • Penicillin & combinations

  • Cephalosporin

  • Nitrofurans

  • others


Based on the Disease Type



  • Gross Hematuria

  • Microscopic Hematuria


Based on the Route of Administration



  • Oral

  • Intravenous

  • Others


Based on the Distribution Channel



  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies


Hematuria Treatment Market Regional Analysis


In terms of region, the global hematuria treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa, as well. The North American region that consists of prominent regions like the US and Canada is projected to be the most attractive market for hematuria treatment during the forecast period. There has been an early adoption of branded products, followed by other factors like favorable medical reimbursement policies, recent FDA approvals, alongside a large number of drugs in the pipeline, rising focus on reducing the number of undiagnosed hematuria cases, and the availability of early treatment are factors anticipated to drive the hematuria treatment market in the U.S. and Canada during the forecast period.


Hematuria Treatment Market Competitive Landscape


The global hematuria treatment market was reported to have been highly fragmented in the historic forecast period that had ended in 2018. The prominent key manufacturers that are operating in the global market are mentioned as follows:



  • Pfizer, Inc.

  • GlaxoSmithKline, Inc.

  • AstraZeneca plc

  • Boehringer Ingelheim GmbH

  • Johnson & Johnson

  • Cipla Ltd.

  • Hoffmann La Roche Ltd.

  • Bristol Myers Squibb

  • Novartis International AG.

  • Teva Pharmaceutical Industries Ltd.

  • Novartis International AG

  • Merck & Co.


Recent Developments


There has been a huge and considerable increase in the number of hematuria therapeutics that are being dispensed through retail pharmacies and it is being followed by the growth in the number of retail pharmacies that are coming into existence in the developing countries which are likely to help make a huge consideration in the market especially during the ongoing forecast period.


The global patients that are located in various market locations prefer retail pharmacies to purchase drugs, as these are easily accessible. The production and manufacturing firms are focusing on easy availability that is helpful for the hematuria treatment market function expansion in the global market premises.


The European region is projected to emerge as the second most attractive market for hematuria treatment. The functioning in the regional markets that are present in the region is driven by the substantial increase in demand for new therapeutics, and other prominent factors like the carrying of extensive research in the field of urinary tract infection care, followed by the geographical expansion of market players.


Hematuria Treatment Market Report Overview


The global market report aims to highlight the functioning of the global market followed by the market dynamics in the form of drivers and restraints that are likely to impact and introduce a change in the global market functioning. Further, the report has been prepared to give market insights to the investors and help them understand the market competition for them to decide. The report carries in-depth research of the role of the key market players and the recent developments undertaken during the period owing to the rising demands for the market processes and functioning.



Report Scope:

Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   2020-2027: Substantial CAGR
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Causes, Treatment, and End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   AstraZeneca Plc. Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Novartis International AG, Pfizer, Inc., Sun Pharmaceutical Industries Limited, The Medicines Company, and others
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Rising frequency rate in numerous types of hematuria
  • Increasing awareness


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The outlook of the hematuria treatment market looks very promising.

    Huge investments for the development of products related to hematuria treatment, rising prevalence of hematuria and increasing awareness, evolving technology such as point-of-care drug delivery systems and focus on delivering best possible care, and rise in the global economy that is widening the access to the quality care are the major tailwinds pushing the growth of the hematuria treatment market.

    North America holds the largest share in the hematuria treatment market, followed by Europe and the Asia Pacific, respectively.

    Bristol-Myers Squibb, AstraZeneca Plc., F. Hoffmann-La Roche Ltd., Janssen Pharmaceuticals, Inc., GlaxoSmithKline Inc., Merck & Co., Pfizer, Inc., Novartis International AG, Sun Pharmaceutical Industries Limited, and The Medicines Company, are some of the major players operating in the hematuria treatment market.

    Strategic initiatives such as mergers & acquisitions, collaborations, expansion, and technology/ product launch are some of the growth strategies that players operating in the global hematuria treatment market adopt to gain a larger competitive advantage.